Bayer Consumer Health Exec Cites the ‘Huge Potential’ of OTC Digital Therapeutics, AI
Article
Commercial
![HBW-Insights-articles_hero](https://www.citeline.com/-/media/citeline/resources/images/hbw-insights-articles_hero.jpg?la=en&h=538&w=1340&hash=77897A8CCF2925C14BED1653D3CC9BCC)
HBW Insight speaks to Bayer Consumer Health's head of R&D and chief scientific officer David Evendon-Challis about the opportunity presented by a new generation of OTC digital therapeutics as well as by AI-driven self-care. Defined by the Digital Therapeutics Alliance as “delivering evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease,” the digital therapeutics sector saw tremendous growth and investor interest during the pandemic.